Possible genetic predisposition to cardiac effects

• Department of Psychiatry, University of Illinois at Chicago, 1601 West Taylor Street, MC912, Chicago, Illinois, 60612, USA

---

• 1. Langton PE, Hankey GJ, Eikelboom JW. Cardiovascular safety of rofecoxib (Vioxx): lessons learned and unanswered questions [editorial]. Med J Aust 2004; 181: 524-525. Previously published online, 26 October 2004. <MJA full text>
• 2. Dwyer JH, Allayee H, Dwyer KM, et al. Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. N Engl J Med 2004; 350: 29-37.
• 3. Helgadottir A, Manolescu A, Thorleifsson G, et al. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet 2004; 36: 233-239.
• 4. Manev R, Manev H. 5-Lipoxygenase as a putative link between cardiovascular and psychiatric disorders. Crit Rev Neurobiol 2004; 16: 177-182.
• 5. FitzGerald GA. Coxibs and cardiovascular disease. N Engl J Med 2004; 351: 1709-1711.